An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue 4, 2015, Pages 752-760

  Van Lumig P P M ^a   Menting, S P ^b   Van Den Reek, J M P A ^a   Spuls, P I ^b   Van Riel, P L C M ^a   Van De Kerkhof, P C M ^a   Fransen, J ^a   Kievit, W ^a   De Jong, E M G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN A; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BASAL CELL CARCINOMA; CANCER RISK; COHORT ANALYSIS; DISEASE DURATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NON MELANOMA SKIN CANCER; PHOTOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; PSORIATIC ARTHRITIS; PUVA; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; SYSTEMIC THERAPY; TREATMENT DURATION; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; MIDDLE AGED; RISK FACTOR; SKIN NEOPLASMS; TIME;

ADALIMUMAB; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; ETANERCEPT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; PHOTOTHERAPY; PSORIASIS; RISK FACTORS; SKIN NEOPLASMS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84925387313     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12675     Document Type: Article

References (21)

1. Pathirana D, Ormerod AD, Saiag P, et al,. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl 2): 1-70.
2. van Lumig PP, Driessen RJ, Berends MA, Boezeman JB, van de Kerkhof PC, de Jong EM,. Safety of treatment with biologics for psoriasis in daily practice: 5-year data. J Eur Acad Dermatol Venereol 2012; 26: 283-291.
3. Smith CH, Anstey AV, Barker JN, et al,. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019.
4. Lecluse LL, de Groot M, Bos JD, Spuls PI,. Experience with biologics for psoriasis in daily practice: switching is worth a try. Br J Dermatol 2009; 161: 948-951.
5. Driessen RJ, Boezeman JB, van de Kerkhof PC, de Jong EM,. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol 2009; 160: 670-675.
6. Kievit W, Fransen J, Adang EM, et al,. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford) 2011; 50: 196-203.
7. Casparie M, Tiebosch AT, Burger G, et al,. Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol. 2007; 29: 19-24.
8. Bailin PL, Tindall JP, Roenigk HH Jr, Hogan MD,. Is methotrexate therapy for psoriasis carcinogenic? A modified retrospective-prospective analysis. JAMA 1975; 232: 359-362.
9. Chakravarty EF, Michaud K, Wolfe F,. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005; 32: 2130-2135.
10. Jensen P, Moller B, Hansen S,. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 2000; 42: 307.
11. Karagas MR, Cushing GL Jr, Greenberg ER, Mott LA, Spencer SK, Nierenberg DW,. Non-melanoma skin cancers and glucocorticoid therapy. Br J Cancer 2001; 85: 683-686.
12. Stern RS, Laird N,. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy Follow-up Study. Cancer 1994; 73: 2759-2764.
13. Stern RS, Zierler S, Parrish JA,. Methotrexate used for psoriasis and the risk of noncutaneous or cutaneous malignancy. Cancer 1982; 50: 869-872.
14. Setshedi M, Epstein D, Winter TA, Myer L, Watermeyer G, Hift R,. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J Gastroenterol Hepatol 2012; 27: 385-389.
15. van Lumig PP, Driessen RJ, Kievit W, Boezeman JB, van de Kerkhof PC, de Jong EM,. Results of three analytical approaches on long-term efficacy of etanercept for psoriasis in daily practice. J Am Acad Dermatol 2013; 68: 57-63.
16. Lim JL, Stern RS,. High levels of ultraviolet B exposure increase the risk of non-melanoma skin cancer in psoralen and ultraviolet A-treated patients. J Invest Dermatol. 2005; 124: 505-513.
17. Ridky TW,. Nonmelanoma skin cancer. J Am Acad Dermatol 2007; 57: 484-501.
18. Stern RS,. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J Am Acad Dermatol 2012; 66: 553-562.
19. Stern RS, Liebman EJ, Vakeva L,. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. J Natl Cancer Inst 1998; 90: 1278-1284.
20. Bavinck JN, Tieben LM, Van der Woude FJ, et al,. Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol 1995; 13: 1933-1938.
21. de Sevaux RG, Smit JV, de Jong EM, van de Kerkhof PC, Hoitsma AJ,. Acitretin treatment of premalignant and malignant skin disorders in renal transplant recipients: clinical effects of a randomized trial comparing two doses of acitretin. J Am Acad Dermatol 2003; 49: 407-412.